# A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors

> **NCT06796907** · PHASE1,PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 392 (estimated)

## Conditions studied

- Tumours, Gynecological

## Interventions

- **DRUG:** GSK5733584
- **DRUG:** Dostarlimab
- **DRUG:** Bevacizumab
- **DRUG:** Anticancer therapy 3
- **DRUG:** Anticancer therapy 4

## Key facts

- **NCT ID:** NCT06796907
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-04
- **Primary completion:** 2027-12-17
- **Final completion:** 2028-04-05
- **Target enrollment:** 392 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06796907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06796907, "A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06796907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*